evaluated CXCL3 – a chemoattractant that organizes cellular architecture of B-cell follicles and germinal centers- and found that patients with CLL with high serum CXCL3 levels had active and advanced stage disease, and a shorter time to treatment (96). Here, CXCL3 is linked to B-cell chronic lymphocytic leukemia.